Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (829)	2/14/2000 7:18:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 3158

biowa, Peter(G) is a good guy, and sharp Yes, but I'm not sure he isn't a year late. The dramatic rise in biotech prices and the even more dramatic opening of the finance window to biotechs means that the prey have gotten an awful lot stronger, quicker and meaner. Certainly in today's environment, AGPH, SIBI and SUGN would all be happy campers if they hadn't been eaten, and so other biotechs are going to look at offers that much more skeptically. Thus I wouldn't be surprised to see the sort of pharma/biotech mergers we saw in 1998 actually tail off. We may yet see a pharma take a run at a bigger biotech like CHIR or GENZ, though. Or even (quick, where's the garlic?) SEPR. I also would expect to see some activity from the nouveau riche genomic crew - for example CRA might well want to move downstream (where else is there to go?) and they have the bucks to do it. Peter